Search results for "Dose finding"

showing 2 items of 2 documents

Safety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma

2019

Abstract Background ABBV-181 is a humanized anti-PD1 monoclonal antibody; dose finding and early safety, PK and pharmacodynamic data have been reported (ESMO18). This report summarizes data from the head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) expansion cohorts in the Ph1 FIH study (NCT03000257). Methods Patients (pts) with previously treated, advanced HNSCC and NSCLC received ABBV-181 IV, 250 mg Q2W or 500 mg Q4W to progression. Response was assessed by RECIST v1.1 and iRECIST. Results As of April 2019, 81 pts were dosed. Table . 1288P n (%) HNSCC n = 41 NSCLC n = 40 Median days on treatment, range 72, 1–407 71, 1–421 Dose: 250 mg/500 mg 31/10 19/21 …

0301 basic medicinemedicine.medical_specialtybusiness.industryAnti pd 1Physical healthStock optionsHematology03 medical and health sciencesNeoplasm progressionDose finding030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinePartial responseMedicinemedicine.symptombusinessHead and neck carcinomaConfusionAnnals of Oncology
researchProduct

A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis.

2014

7022^ Background: Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by dysregulation of the Janus kinase (JAK) pathway resulting in bone marrow fibrosis, splenomegaly, and debilitat...

Cancer ResearchRuxolitinibPathologymedicine.medical_specialtybusiness.industryBone marrow fibrosismedicine.diseasechemistry.chemical_compoundDose findingOncologychemistryPanobinostatCancer researchMedicineIn patientbusinessJanus kinaseMyelofibrosisMyeloproliferative neoplasmmedicine.drugJournal of Clinical Oncology
researchProduct